neoantigen DNA vaccine / Imunon - LARVOL DELTA

A novel formulated neoantigen DNA vaccine with promising anticancer efficacy in B16F10 mouse melanoma model (AACR 2025) - "All animals in the adjuvant groups also lived longer. The anti-tumor efficacy results are supported by the onset of robust T-cell responses in all treatment groups supporting the involvement of immune activation in the action of this novel DNA vaccine that does not require a virus or device and can be manufactured rapidly with a simple and cost-effective manufacturing process critical for the viability of cancer vaccines."

Preclinical • Tumor-specific neoantigens • Melanoma • Oncology • Solid Tumor • IL12A